Bse MidCap Select Index

Glenmark Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Thursday, November 5, 2026, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Further noted that the notice of the aforesaid meeting is also being made available on the website of the Company in terms of Regulation 46(2) of the SEBI LODR. The Unaudited Financial Results of the Company shall be submitted to the Stock Exchanges after the conclusion of the aforesaid Board Meeting on Thursday, November 5, 2026, and will also be hosted on the website of the Company on the said date and thereafter shall be published in the newspapers, in accordance with the SEBI LODR. Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and Company’s Code of Conduct for Prevention of Insider Trading, the Company has already informed the Stock Exchanges vide its letter dated September 28, 2026 that the window for trading in securities of the Company for the Designated Persons viz, Directors, Key Managerial Personnel, Identified Employees / Persons of the Company including the Immediate Relatives of the Designated Persons and the Connected Persons, etc. would remain closed from October 01, 2026 till the expiry of 48 hours after the declaration of Unaudited Financial results for the quarter and half year ended September 30, 2026 and accordingly, the trading window shall remain closed till Saturday, November 07, 2026 and shall re-open thereafter, i.e. on Sunday, November 08, 2026. 

The above information is a part of company’s filings submitted to BSE.

Persistent Systems has informed that ICRA, its letters dated October 22, 2026, has continued the Issuer Rating of the Company and assigned/continued the credit ratings for the Company’s proposed issuance of Non-Convertible Debentures and Commercial Paper as details 

The above information is a part of company’s filings submitted to BSE.

PB Fintech has informed that it enclosed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

Persistent Systems has informed that the Special Committee of Board of Directors at its meeting held on Friday, October 16, 2026, commenced at 1002 Hrs (IST) and concluded at 1020 Hrs. (IST), has inter-alia considered and approved the terms of issuance of Non-Convertible Debentures and Commercial Paper as a part of long term debt financing in relation to the acquisition of Nagarro SE. The requisite disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, (‘the SEBI Circulars’) are as follows: In terms of recommendation of the Board of Directors dated September 2, 2026, subsequent to the approval of the Members of the Company sought in the Extraordinary General Meeting held on October 5, 2026, and pursuant to the authority delegated by the Board of Directors vide its resolution dated October 15, 2026, approving the re-constitution of the Special Committee of Directors and its terms of reference, the Special Committee of the Board of Directors approved the terms of issuance of Non-Convertible Debentures (NCDs) amounting up to INR 8,000 Crores (INR Eight Thousand Crores only) in accordance with the applicable laws as per details enclosed.

The above information is a part of company’s filings submitted to BSE.

Federal Bank has informed that based on the recommendations of the Nomination, Remuneration, Ethics and Compensation Committee and pursuant to the Banking Regulation Act, 1949 and the Reserve Bank of India (Commercial Banks - Governance) Directions, 2025, the Board of Directors of the Bank at its meeting held today, Friday, October 16, 2026 has approved the appointment of Rajesh Varrier (DIN: 00105765) as an Additional Director (Non-Executive Independent Director) on the Board of the Bank, for a period of three consecutive years with effect from October 16, 2026. Pursuant to Regulation 17(1C) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, shareholders’ approval for the appointment of Rajesh Warrier (DIN: 00105765) shall be obtained at the next general meeting or within a period of three months from the date of appointment, whichever is earlier. In terms of Section 149(13) of the Companies Act, 2013, he shall not be liable to retire by rotation during his tenure as an Independent director of the Bank. Rajesh Varrier is not related to any of the Directors or Key Managerial Personnel of the Bank. Further, in line with the Stock Exchange Circular dated June 20, 2018, it is hereby confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

The above information is a part of company’s filings submitted to BSE.